Repligen (NASDAQ:RGEN) Earns Peer Perform Rating from Analysts at Wolfe Research

Research analysts at Wolfe Research began coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued to investors on Thursday,Briefing.com Automated Import reports. The firm set a “peer perform” rating on the biotechnology company’s stock.

Several other research firms also recently commented on RGEN. JPMorgan Chase & Co. increased their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. UBS Group decreased their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Wells Fargo & Company started coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price for the company. Finally, Stephens reaffirmed an “overweight” rating and set a $170.00 target price on shares of Repligen in a research note on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Repligen has an average rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Price Performance

Shares of RGEN stock opened at $150.47 on Thursday. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a market cap of $8.43 billion, a P/E ratio of -406.66, a P/E/G ratio of 4.27 and a beta of 0.96. The business has a fifty day simple moving average of $141.59 and a 200 day simple moving average of $144.78.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the company earned $0.23 earnings per share. On average, sell-side analysts forecast that Repligen will post 1.45 EPS for the current fiscal year.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

A number of hedge funds have recently bought and sold shares of RGEN. QRG Capital Management Inc. lifted its holdings in Repligen by 31.2% during the first quarter. QRG Capital Management Inc. now owns 3,576 shares of the biotechnology company’s stock worth $658,000 after acquiring an additional 850 shares during the period. Russell Investments Group Ltd. lifted its holdings in Repligen by 5.2% during the first quarter. Russell Investments Group Ltd. now owns 35,134 shares of the biotechnology company’s stock worth $6,463,000 after acquiring an additional 1,746 shares during the period. State Board of Administration of Florida Retirement System lifted its holdings in Repligen by 4.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 64,035 shares of the biotechnology company’s stock worth $10,781,000 after acquiring an additional 2,520 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Repligen by 30.2% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock worth $5,312,000 after acquiring an additional 6,705 shares during the period. Finally, Nicolet Advisory Services LLC lifted its holdings in Repligen by 55.4% during the first quarter. Nicolet Advisory Services LLC now owns 2,249 shares of the biotechnology company’s stock worth $409,000 after acquiring an additional 802 shares during the period. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.